JP2012522055A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522055A5 JP2012522055A5 JP2012503526A JP2012503526A JP2012522055A5 JP 2012522055 A5 JP2012522055 A5 JP 2012522055A5 JP 2012503526 A JP2012503526 A JP 2012503526A JP 2012503526 A JP2012503526 A JP 2012503526A JP 2012522055 A5 JP2012522055 A5 JP 2012522055A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- drug
- particles
- item
- average molecular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 claims description 329
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 221
- 239000003814 drug Substances 0.000 claims description 189
- 229940079593 drug Drugs 0.000 claims description 169
- 229960003668 docetaxel Drugs 0.000 claims description 111
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 104
- 229920000642 polymer Polymers 0.000 claims description 97
- 230000002209 hydrophobic effect Effects 0.000 claims description 93
- 239000000562 conjugate Substances 0.000 claims description 83
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 76
- 239000003795 chemical substances by application Substances 0.000 claims description 46
- 239000000580 polymer-drug conjugate Substances 0.000 claims description 46
- 239000000178 monomer Substances 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 24
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 22
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 22
- 239000004615 ingredient Substances 0.000 claims description 21
- 239000004094 surface-active agent Substances 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 17
- 229920001519 homopolymer Polymers 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 14
- 229940123237 Taxane Drugs 0.000 claims description 13
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 13
- 125000002252 acyl group Chemical group 0.000 claims description 12
- 229910052697 platinum Inorganic materials 0.000 claims description 12
- 235000014655 lactic acid Nutrition 0.000 claims description 11
- 239000004310 lactic acid Substances 0.000 claims description 11
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- 229940041181 antineoplastic drug Drugs 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 239000002577 cryoprotective agent Substances 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 230000002491 angiogenic effect Effects 0.000 claims description 3
- 239000002256 antimetabolite Substances 0.000 claims description 3
- 229960001573 cabazitaxel Drugs 0.000 claims description 3
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 229950005692 larotaxel Drugs 0.000 claims description 3
- SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 102
- 206010028980 Neoplasm Diseases 0.000 description 63
- 201000011510 cancer Diseases 0.000 description 63
- 208000035475 disorder Diseases 0.000 description 33
- 206010006187 Breast cancer Diseases 0.000 description 28
- 208000026310 Breast neoplasm Diseases 0.000 description 21
- 230000001394 metastastic effect Effects 0.000 description 21
- 206010061289 metastatic neoplasm Diseases 0.000 description 21
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 229940044683 chemotherapy drug Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 7
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 206010070308 Refractory cancer Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical group CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010038111 Recurrent cancer Diseases 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16472809P | 2009-03-30 | 2009-03-30 | |
| US16472209P | 2009-03-30 | 2009-03-30 | |
| US16472009P | 2009-03-30 | 2009-03-30 | |
| US16473109P | 2009-03-30 | 2009-03-30 | |
| US16473409P | 2009-03-30 | 2009-03-30 | |
| US16472509P | 2009-03-30 | 2009-03-30 | |
| US61/164,731 | 2009-03-30 | ||
| US61/164,734 | 2009-03-30 | ||
| US61/164,725 | 2009-03-30 | ||
| US61/164,720 | 2009-03-30 | ||
| US61/164,722 | 2009-03-30 | ||
| US61/164,728 | 2009-03-30 | ||
| US26299309P | 2009-11-20 | 2009-11-20 | |
| US26299409P | 2009-11-20 | 2009-11-20 | |
| US61/262,994 | 2009-11-20 | ||
| US61/262,993 | 2009-11-20 | ||
| PCT/US2010/028770 WO2010117668A1 (en) | 2009-03-30 | 2010-03-26 | Polymer-agent conjugates, particles, compositions, and related methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015051314A Division JP2015117250A (ja) | 2009-03-30 | 2015-03-13 | ポリマー‐薬剤抱合体、粒子、組成物、および関連する使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012522055A JP2012522055A (ja) | 2012-09-20 |
| JP2012522055A5 true JP2012522055A5 (https=) | 2013-04-25 |
Family
ID=42936493
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012503526A Pending JP2012522055A (ja) | 2009-03-30 | 2010-03-26 | ポリマー‐薬剤抱合体、粒子、組成物、および関連する使用方法 |
| JP2015051314A Pending JP2015117250A (ja) | 2009-03-30 | 2015-03-13 | ポリマー‐薬剤抱合体、粒子、組成物、および関連する使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015051314A Pending JP2015117250A (ja) | 2009-03-30 | 2015-03-13 | ポリマー‐薬剤抱合体、粒子、組成物、および関連する使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US20100247668A1 (https=) |
| EP (1) | EP2413901A4 (https=) |
| JP (2) | JP2012522055A (https=) |
| CN (2) | CN103932972A (https=) |
| AU (1) | AU2010234916A1 (https=) |
| BR (1) | BRPI1014854A2 (https=) |
| CA (1) | CA2756072A1 (https=) |
| EA (1) | EA201171195A8 (https=) |
| IL (1) | IL215123A0 (https=) |
| MX (1) | MX2011010390A (https=) |
| WO (1) | WO2010117668A1 (https=) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2377318T3 (es) | 2002-09-06 | 2012-03-26 | Cerulean Pharma Inc. | Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| US8318211B2 (en) | 2008-06-16 | 2012-11-27 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| EA020954B1 (ru) | 2008-06-16 | 2015-03-31 | Бинд Терапьютикс, Инк. | Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| US8563041B2 (en) | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
| WO2010114770A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
| CA2756072A1 (en) * | 2009-03-30 | 2010-10-14 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
| AU2010295646B2 (en) * | 2009-09-15 | 2016-02-11 | Ellipses Pharma Limited | Treatment of cancer |
| ES2862340T3 (es) | 2009-10-29 | 2021-10-07 | Sanofi Mature Ip | Nuevo uso antitumoral de cabazitaxel |
| DK2509634T3 (en) | 2009-12-11 | 2019-04-23 | Pfizer | Stable formulations for lyophilization of therapeutic particles |
| WO2011084521A2 (en) * | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same |
| EP2515942B1 (en) | 2009-12-15 | 2020-02-12 | Pfizer Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
| WO2011119995A2 (en) * | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Formulations and methods of use |
| US20120213854A1 (en) * | 2010-09-30 | 2012-08-23 | Fetzer Oliver S | Methods of treating a subject and related particles, polymers and compositions |
| US10064406B2 (en) | 2011-01-06 | 2018-09-04 | Cytosorbents Corporation | Polymeric sorbent for removal of impurities from whole blood and blood products |
| US20140017165A1 (en) * | 2011-01-11 | 2014-01-16 | Zhuang Wang | Dna repair enzyme inhibitor nanoparticles and uses thereof |
| CA2825016C (en) * | 2011-01-24 | 2021-02-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nanoparticles for dermal and systemic delivery of drugs |
| CN102617517B (zh) * | 2011-01-27 | 2015-11-18 | 李勤耕 | 一类新的7,10-o,o-二甲多西紫杉醇衍生物及其应用 |
| US20180326081A1 (en) * | 2011-06-06 | 2018-11-15 | Starpharma Pty Ltd | Macromolecules |
| AU2012294326A1 (en) * | 2011-08-10 | 2013-03-21 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy |
| CN102408397B (zh) * | 2011-10-19 | 2014-08-20 | 上海贝美医药科技有限公司 | 紫杉烷类衍生物及其制备方法 |
| EP3560486A1 (en) * | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| WO2013115965A1 (en) * | 2012-01-31 | 2013-08-08 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
| WO2013126552A1 (en) | 2012-02-21 | 2013-08-29 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
| US20140037573A1 (en) * | 2012-02-22 | 2014-02-06 | Cerulean Pharma Inc. | Conjugates, particles, compositions, and related methods |
| MX2014010209A (es) * | 2012-02-29 | 2014-11-21 | Toray Industries | Agente inhibidor para acumulacion de fluido de la cavidad corporal. |
| CA2868302A1 (en) | 2012-03-23 | 2013-09-26 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| ES3055223T3 (en) | 2012-05-03 | 2026-02-10 | Alcon Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| JP6360039B2 (ja) | 2012-05-03 | 2018-07-18 | カラ ファーマシューティカルズ インコーポレイテッド | 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法 |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| CN111700879A (zh) * | 2012-05-03 | 2020-09-25 | 卡拉制药公司 | 显示提高的粘膜转移的药物纳米粒子 |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| WO2013179310A1 (en) * | 2012-05-31 | 2013-12-05 | Mylan Laboratories Limited | Stable aqueous compositions of pemetrexed |
| JP6280546B2 (ja) | 2012-06-26 | 2018-02-14 | デル マー ファーマシューティカルズ | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
| WO2014015422A1 (en) * | 2012-07-27 | 2014-01-30 | Ontario Institute For Cancer Research | Cellulose-based nanoparticles for drug delivery |
| TWI471260B (zh) | 2012-08-20 | 2015-02-01 | Nat Univ Tsing Hua | 製備奈米粒子之連續反應裝置及製備奈米粒子之方法 |
| WO2014043618A1 (en) | 2012-09-17 | 2014-03-20 | Bind Therapeutics, Inc. | Process for preparing therapeutic nanoparticles |
| US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| GB201220675D0 (en) * | 2012-11-16 | 2013-01-02 | Univ Singapore | Process and materials for medical applications |
| CN103845290A (zh) | 2012-12-03 | 2014-06-11 | 曼丽国际有限公司 | Umirolimus及其衍生物用于治疗癌症的用途 |
| TW201427681A (zh) * | 2013-01-07 | 2014-07-16 | Superlab Far East Ltd | 用空間構象改變的重組干擾素治療腫瘤的方法 |
| CN103044364B (zh) * | 2013-01-07 | 2016-01-20 | 重庆泰濠制药有限公司 | 一种卡巴他赛无定形晶及其制备方法 |
| US20150358920A1 (en) * | 2013-01-14 | 2015-12-10 | Telefonaktiebolaget L M Ericsson (Publ) | Handling uplink transmit power reporting |
| US20150104520A1 (en) * | 2013-04-05 | 2015-04-16 | Vuong Trieu | Nanoparticle Formulations in Biomarker Detection |
| KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
| TWI632916B (zh) * | 2013-07-29 | 2018-08-21 | 林仁政 | 增強治療急性中風之抗血小板藥物之遞送方法及其組合物 |
| TW201503900A (zh) * | 2013-07-29 | 2015-02-01 | ren-zheng Lin | 增強治療急性中風之抗血小板藥物之遞送方法及其組合物 |
| CA2920835A1 (en) | 2013-08-20 | 2015-02-26 | Anutra Medical, Inc. | Syringe fill system and method |
| WO2015106094A1 (en) * | 2014-01-10 | 2015-07-16 | Atossa Genetics Inc. | Transpapillary methods and compositions for diagnosing and treating breast conditions |
| US9669137B2 (en) * | 2014-02-04 | 2017-06-06 | Abbott Cardiovascular Systems Inc. | Modified polylactide polymers |
| PE20170312A1 (es) | 2014-03-14 | 2017-03-30 | Pfizer | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso |
| WO2015187847A1 (en) * | 2014-06-03 | 2015-12-10 | Cure-It Lifesciences, Llc | Use of prostaglandin e1 (pge1) and misoprostol for treating chronic myelogenous/myeloid leukemia (cml) |
| WO2016004043A1 (en) * | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| BR112018000217A2 (pt) * | 2015-07-15 | 2018-09-04 | Celator Pharmaceuticals Inc | sistemas de distribuição de nanopartículas aperfeiçoados |
| KR101726728B1 (ko) | 2015-07-28 | 2017-04-14 | 주식회사 삼양바이오팜 | 고분자 담체 함유 약학 조성물의 유연물질 분석 방법 |
| US20170028078A1 (en) * | 2015-07-28 | 2017-02-02 | Layerbio, Inc. | Sustained-release drug formulations for glaucoma |
| JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| AU2016326747A1 (en) | 2015-09-25 | 2018-03-01 | Zy Therapeutics Inc. | Drug formulation based on particulates comprising polysaccharide-vitamin conjugate |
| RU2736590C2 (ru) | 2016-02-16 | 2020-11-18 | Стронгбридж Даблин Лимитед | Велдореотид, обладающий плохой растворимостью в физиологических условиях, для применения при лечении акромегалии, акромегалии со злокачественным новообразованием, экспрессирующих sst-r5 опухолей, диабета 2 типа, гипергликемии и опухолей, связанных с гормонами |
| KR20180112060A (ko) | 2016-02-23 | 2018-10-11 | 타베다 세라퓨틱스, 인코포레이티드 | Hsp90 표적화된 접합체 및 이의 입자 및 제형 |
| US20190099374A1 (en) * | 2016-03-25 | 2019-04-04 | Pfizer Inc. | Stable formulations for lyophilizing therapeutic particles |
| US20200323811A1 (en) * | 2016-05-24 | 2020-10-15 | Industry-University Cooperation Foundation Hanyang University | Intranasal pharmaceutical composition comprising anticancer drugcontaining nanoparticles for treating brain diseases |
| KR101902906B1 (ko) * | 2017-03-06 | 2018-10-02 | 주식회사 삼양바이오팜 | 고분자 담체 함유 약학 조성물 평가의 기준물질로서의 유연물질 |
| US12089928B2 (en) | 2017-05-18 | 2024-09-17 | Wear2B Ltd. | Device, system and method for non-invasive monitoring of physiological measurements |
| JP7601375B2 (ja) * | 2017-12-01 | 2024-12-17 | ザ チルドレンズ メディカル センター コーポレーション | 長時間の局所麻酔のための麻酔薬－ポリマー共有結合性コンジュゲート |
| WO2020014750A1 (en) | 2018-07-19 | 2020-01-23 | Starpharma Pty Ltd | Therapeutic dendrimer |
| US12071517B2 (en) | 2018-07-19 | 2024-08-27 | Starpharma Pty Ltd. | Therapeutic dendrimer |
| JP7542529B2 (ja) | 2018-10-17 | 2024-08-30 | バイオラインアールエックス・リミテッド | 転移性膵臓腺癌の処置 |
| BR112021007969A2 (pt) | 2018-10-29 | 2021-07-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | complexos de tetraciclina com atividade controlada |
| CN109224119B (zh) * | 2018-10-30 | 2021-02-23 | 北京大学深圳医院 | 一种π共轭纳米自组装颗粒瘤内注射栓塞肿瘤血管抗癌剂 |
| WO2020148745A1 (en) | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
| WO2020148744A1 (en) | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
| CN111467487A (zh) * | 2019-01-24 | 2020-07-31 | 中国科学院过程工程研究所 | 阳离子脂质纳米疫苗佐剂及其制备方法 |
| TW202112364A (zh) * | 2019-08-16 | 2021-04-01 | 美商蜻蛉治療股份有限公司 | 投與替司他賽(tesetaxel)與cyp3a4誘導劑之糖皮質素之方法 |
| CN111215249B (zh) * | 2019-11-29 | 2022-05-27 | 南华大学 | 一种提取碳酸铀酰离子的方法 |
| CN112111791B (zh) * | 2020-09-01 | 2021-07-23 | 杭州新天元织造有限公司 | 一种基于环保的高弹力无色差的服装面料零染色纺工艺 |
| CN112156283A (zh) * | 2020-09-28 | 2021-01-01 | 上海中冶医院 | 一种胰岛素注射腹部表盘定位装置及使用方法 |
| CN112390909B (zh) * | 2020-11-16 | 2022-09-02 | 西安工程大学 | pH/盐双敏型醚基功能化聚离子液体凝胶制备方法及应用 |
| WO2024123732A1 (en) * | 2022-12-05 | 2024-06-13 | Dantari, Inc. | Compositions and methods for treatment of prostate cancer |
| US11833224B1 (en) | 2023-02-08 | 2023-12-05 | Leuvian Llc | Lyoprotectant compositions and uses thereof |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5718921A (en) * | 1987-03-13 | 1998-02-17 | Massachusetts Institute Of Technology | Microspheres comprising polymer and drug dispersed there within |
| US5356633A (en) * | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| US5527528A (en) * | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
| CA2087125A1 (en) * | 1992-01-23 | 1993-07-24 | Mridula Nair | Chemically fixed micelles |
| US5820879A (en) * | 1993-02-12 | 1998-10-13 | Access Pharmaceuticals, Inc. | Method of delivering a lipid-coated condensed-phase microparticle composition |
| CA2472404A1 (en) * | 1993-07-19 | 1995-02-02 | Angiotech Pharmaceuticals, Inc. | Combination of stent and anti-angiogenic factor |
| US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5500161A (en) * | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
| ZA949182B (en) * | 1993-12-02 | 1995-07-26 | South African Druggists Ltd | Pharmaceutical composition |
| EP0788346B9 (en) * | 1994-03-18 | 2007-02-14 | Supernus Pharmaceuticals, Inc. | Emulsified drug delivery systems |
| US6007845A (en) * | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| EP0752245B1 (en) * | 1995-07-05 | 2002-05-22 | European Community | Biocompatible and biodegradable nanoparticles designed for proteinaceous drugs absorption and delivery |
| KR0180334B1 (ko) * | 1995-09-21 | 1999-03-20 | 김윤 | 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법 |
| DE69625326T2 (de) * | 1995-09-29 | 2003-09-18 | Japan Science And Technology Corp., Kawaguchi | Anthracyclinderivate und sie enthaldende medizinische zubereitungen |
| US6126919A (en) * | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| US20050025819A1 (en) * | 1997-07-14 | 2005-02-03 | Hayat Onyuksel | Materials and methods for making improved micelle compositions |
| US6254890B1 (en) * | 1997-12-12 | 2001-07-03 | Massachusetts Institute Of Technology | Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids |
| BR9813548A (pt) * | 1997-12-12 | 2000-10-10 | Samyang Corp | Micelas poliméricas misturadas biodegradáveis para distribuição de gene |
| KR19990085365A (ko) * | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6429200B1 (en) * | 1998-07-17 | 2002-08-06 | Mirus Corporation | Reverse micelles for delivery of nucleic acids |
| US6165509A (en) * | 1998-09-01 | 2000-12-26 | University Of Washington | Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto |
| US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| KR100360827B1 (ko) * | 1999-08-14 | 2002-11-18 | 주식회사 삼양사 | 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법 |
| US6649138B2 (en) * | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
| KR100446101B1 (ko) * | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
| CA2440935A1 (en) * | 2001-03-13 | 2002-09-19 | Richard Liggins | Micellar drug delivery vehicles and precursors thereto and uses thereof |
| US20030157170A1 (en) * | 2001-03-13 | 2003-08-21 | Richard Liggins | Micellar drug delivery vehicles and precursors thereto and uses thereof |
| EP1383445A4 (en) * | 2001-03-20 | 2005-04-13 | Cydex Inc | FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN |
| US20020192286A1 (en) * | 2001-03-27 | 2002-12-19 | Macromed, Incorporated | Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof |
| US20030026831A1 (en) * | 2001-04-20 | 2003-02-06 | Aparna Lakkaraju | Anionic liposomes for delivery of bioactive agents |
| NZ530588A (en) * | 2001-07-14 | 2005-06-24 | Samyang Corp | Positively charged amphiphilic block copolymer as drug carrier and complex thereof with negatively charged drug |
| US20040208844A1 (en) * | 2001-08-01 | 2004-10-21 | Francis Ignatious | Products and drug delivery vehicles |
| US6592899B2 (en) * | 2001-10-03 | 2003-07-15 | Macromed Incorporated | PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water |
| EP1448707B1 (en) * | 2001-10-18 | 2007-08-22 | Samyang Corporation | Polymeric micelle composition with improved stability |
| WO2003041689A1 (en) * | 2001-11-12 | 2003-05-22 | Alkermes Controlled Therapeutics, Inc. | Biocompatible polymer blends and uses thereof |
| EP1458365A1 (en) * | 2001-12-21 | 2004-09-22 | Celator Technologies Inc. | Improved polymer-lipid delivery vehicles |
| US20030235619A1 (en) * | 2001-12-21 | 2003-12-25 | Christine Allen | Polymer-lipid delivery vehicles |
| EP1480619B1 (en) * | 2002-03-07 | 2013-08-07 | Biocompatibles UK Limited | Drug carriers comprising amphiphilic block copolymers |
| AU2003230761A1 (en) * | 2002-03-29 | 2003-10-13 | Abbott Laboratories | Polymeric micelle formulations of hydrophobic compounds and methods |
| WO2003092665A2 (en) * | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
| US7649023B2 (en) * | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
| AU2003278918A1 (en) * | 2002-09-23 | 2004-04-08 | The General Hospital Coporation | Methods for diagnosing and treating tumors and suppressing cd promoters |
| US7723509B2 (en) * | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| US7311901B2 (en) * | 2003-10-10 | 2007-12-25 | Samyang Corporation | Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery |
| WO2005074913A2 (en) * | 2004-01-30 | 2005-08-18 | Angiotech International Ag | Compositions and methods for treating contracture |
| US20050266067A1 (en) * | 2004-03-02 | 2005-12-01 | Shiladitya Sengupta | Nanocell drug delivery system |
| US20070053845A1 (en) * | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
| US20080274454A1 (en) * | 2004-04-07 | 2008-11-06 | Mirkin Chad A | Reversible and Chemically Programmable Micelle Assembly With Dna Block-Copolymer Amphiphiles |
| ATE531391T1 (de) * | 2004-05-06 | 2011-11-15 | Samyang Corp | Abgabesystem für biologisch wirksame mittel auf basis eines polymeren arzneiträgers mit einem ampiphilen blockpolymer und einem polymilchsäure- derivat |
| WO2006080951A2 (en) * | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
| AU2005269800B8 (en) * | 2004-07-19 | 2011-12-01 | Jazz Pharmaceuticals Therapeutics, Inc. | Particulate constructs for release of active agents |
| US20060193787A1 (en) * | 2005-01-31 | 2006-08-31 | Si-Shen Feng | Nanoparticle-based drug delivery system |
| KR20070114753A (ko) * | 2005-02-18 | 2007-12-04 | 아브락시스 바이오사이언스 인크. | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| WO2006099445A2 (en) * | 2005-03-14 | 2006-09-21 | Massachusetts Institute Of Technology | Nanocells for diagnosis and treatment of diseases and disorders |
| WO2006122223A2 (en) * | 2005-05-10 | 2006-11-16 | Emory University | Strategies for delivery of active agents using micelles and particles |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| WO2007038625A2 (en) * | 2005-09-28 | 2007-04-05 | Northwestern University | Biodegradable nanocomposites with enhanced mechanical properties for soft tissue engineering. |
| US7501179B2 (en) * | 2005-12-21 | 2009-03-10 | Boston Scientific Scimed, Inc. | Block copolymer particles |
| KR100995390B1 (ko) * | 2006-01-02 | 2010-11-19 | 주식회사 삼양제넥스 | 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법 |
| JP5630998B2 (ja) * | 2006-05-15 | 2014-11-26 | マサチューセッツ インスティテュート オブ テクノロジー | 機能的粒子のためのポリマー |
| US20080193536A1 (en) * | 2006-08-14 | 2008-08-14 | Alireza Khademhosseini | Cell-Laden Hydrogels |
| KR100809366B1 (ko) * | 2006-08-21 | 2008-03-05 | 한국과학기술연구원 | 단일 나노입자를 포함하는 유무기 복합체 나노입자 및 이의제조방법 |
| US20100008998A1 (en) * | 2006-09-26 | 2010-01-14 | Samyang Corporation | Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof |
| US20080176958A1 (en) * | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| EP2132133A4 (en) * | 2007-03-02 | 2013-04-17 | Univ Illinois | RELEASE OF PARTICULATE ACTIVE SUBSTANCES |
| US20080311040A1 (en) * | 2007-03-06 | 2008-12-18 | Flagship Ventures | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA |
| JP2010523595A (ja) * | 2007-04-04 | 2010-07-15 | マサチューセッツ インスティテュート オブ テクノロジー | ポリ（アミノ酸）ターゲッティング部分 |
| MX2009010907A (es) * | 2007-04-13 | 2010-03-17 | Univ North Texas | Formulacion del agente activo cargado en nanoparticulas de plga activadas para nano-terapeuticos direccionados para el cancer. |
| EP2436376B1 (en) * | 2007-09-28 | 2014-07-09 | BIND Therapeutics, Inc. | Cancer cell targeting using nanoparticles |
| US20090312402A1 (en) * | 2008-05-20 | 2009-12-17 | Contag Christopher H | Encapsulated nanoparticles for drug delivery |
| US8414879B2 (en) * | 2008-05-20 | 2013-04-09 | The Board Of Trustees Of The University Of Illinois | Superporous hydrogel with cells encapsulated therein and method for producing the same |
| JP2011525180A (ja) * | 2008-06-16 | 2011-09-15 | バインド バイオサイエンシズ インコーポレイテッド | 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法 |
| EA020954B1 (ru) * | 2008-06-16 | 2015-03-31 | Бинд Терапьютикс, Инк. | Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака |
| US8318211B2 (en) * | 2008-06-16 | 2012-11-27 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| EP2306991B1 (en) * | 2008-06-27 | 2019-12-25 | Tepha, Inc. | Injectable delivery of microparticles and compositions therefore |
| US20100087337A1 (en) * | 2008-09-10 | 2010-04-08 | Bind Biosciences, Inc. | High Throughput Fabrication of Nanoparticles |
| US8563041B2 (en) * | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| CA2756072A1 (en) * | 2009-03-30 | 2010-10-14 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
| WO2010114768A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-epothilone conjugates, particles, compositions, and related methods of use |
| WO2010114770A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
-
2010
- 2010-03-26 CA CA2756072A patent/CA2756072A1/en not_active Abandoned
- 2010-03-26 EP EP10762122.9A patent/EP2413901A4/en not_active Withdrawn
- 2010-03-26 CN CN201410161936.2A patent/CN103932972A/zh active Pending
- 2010-03-26 EA EA201171195A patent/EA201171195A8/ru unknown
- 2010-03-26 WO PCT/US2010/028770 patent/WO2010117668A1/en not_active Ceased
- 2010-03-26 AU AU2010234916A patent/AU2010234916A1/en not_active Abandoned
- 2010-03-26 MX MX2011010390A patent/MX2011010390A/es not_active Application Discontinuation
- 2010-03-26 CN CN201080014516.1A patent/CN102378626B/zh not_active Expired - Fee Related
- 2010-03-26 BR BRPI1014854A patent/BRPI1014854A2/pt not_active IP Right Cessation
- 2010-03-26 JP JP2012503526A patent/JP2012522055A/ja active Pending
- 2010-03-29 US US12/748,637 patent/US20100247668A1/en not_active Abandoned
- 2010-09-29 US US12/894,040 patent/US20110189092A1/en not_active Abandoned
-
2011
- 2011-01-11 US US13/004,838 patent/US20110268658A1/en not_active Abandoned
- 2011-09-13 IL IL215123A patent/IL215123A0/en unknown
-
2012
- 2012-07-12 US US13/548,143 patent/US20120282306A1/en not_active Abandoned
- 2012-07-12 US US13/548,108 patent/US20130011445A1/en not_active Abandoned
-
2013
- 2013-03-19 US US13/847,391 patent/US20140099263A1/en not_active Abandoned
- 2013-10-08 US US14/048,537 patent/US20140286873A1/en not_active Abandoned
-
2015
- 2015-03-13 JP JP2015051314A patent/JP2015117250A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012522055A5 (https=) | ||
| Zhao et al. | Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy | |
| Saneja et al. | Gemcitabine and betulinic acid co-encapsulated PLGA− PEG polymer nanoparticles for improved efficacy of cancer chemotherapy | |
| Zhang et al. | Polymeric micelles: nanocarriers for cancer-targeted drug delivery | |
| Chin et al. | Ratiometric delivery of cisplatin and doxorubicin using tumour-targeting carbon-nanotubes entrapping platinum (IV) prodrugs | |
| EP2515946B1 (en) | Nanoconjugates and nanoconjugate formulations | |
| Tan et al. | Recent developments in d-α-tocopheryl polyethylene glycol-succinate-based nanomedicine for cancer therapy | |
| Chuan et al. | Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly (ethylene glycol)–drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo | |
| Xu et al. | The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells | |
| Wu et al. | Nanoparticle-based combination therapy for ovarian cancer | |
| CN102120036B (zh) | 生物降解的高分子键合Pt(IV)类抗癌药物纳米胶束及其制备方法 | |
| Jan et al. | In vitro anti-leukemic assessment and sustained release behaviour of cytarabine loaded biodegradable polymer based nanoparticles | |
| Asyikin binti Abdul Aziz et al. | Recent advances in drug delivery of polymeric nano-micelles | |
| JP2012512175A5 (https=) | ||
| Fan et al. | Folic acid-modified β-cyclodextrin nanoparticles as drug delivery to load DOX for liver cancer therapeutics | |
| Mierina et al. | Delivery systems for birch-bark triterpenoids and their derivatives in anticancer research | |
| Liu et al. | Drug Self‐Delivery Systems: Molecule Design, Construction Strategy, and Biological Application | |
| Jogi et al. | Carbon nanotubes in the delivery of anticancer herbal drugs | |
| Panigrahi et al. | Nanoparticle-mediated diagnosis, treatment, and prevention of breast cancer | |
| CN102641246A (zh) | 一种抗肿瘤的双药纳米载药微球及其制备方法 | |
| Zhang et al. | Advances in nanoscale carrier-based approaches to reduce toxicity and enhance efficacy of podophyllotoxin | |
| AU2016326747A1 (en) | Drug formulation based on particulates comprising polysaccharide-vitamin conjugate | |
| Li et al. | Hypocrellin B‐loaded, folate‐conjugated polymeric micelle for intraperitoneal targeting of ovarian cancer in vitro and in vivo | |
| Karati et al. | A comprehensive review on targeted cancer therapy: new face of treatment approach | |
| Sun et al. | Targeting CD44-positive ovarian cancers via engineered paclitaxel prodrug nanoparticles for enhanced chemotherapeutic efficacy |